Using ELISA and IHC, we confirmed that VEGF secretion in the peripheral blood and VEGF levels in the bone marrow of MDS patients were significantly increased in higher-risk group compared with those in lower-risk group according to the IPSS-R classification. This evidence concerns the gene VEGFA and myelodysplastic syndrome.